How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

65,172 results for

Type 1 Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. VA/DoD clinical practice guideline for the management of type 2 diabetes mellitus in primary care.

a diagnosis of type 2 diabetes mellitus (T2DM). If the percentage is less than 80%, then data must have been reported separately for this patient subgroup. Key Question Specific Criteria For KQ 1, acceptable study designs included SRs, randomized controlled trials (RCTs), including follow-up studies of RCTs, cohorts and pre-planned, prospective analyses of those studies. Retrospective analyses were not included. For KQs 2-4, 8, and 9, acceptable study designs included SRs of RCTs and/or individual RCTs (...) VA/DoD clinical practice guideline for the management of type 2 diabetes mellitus in primary care. VA/DoD clinical practice guideline for the management of type 2 diabetes mellitus in primary care. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 03 Oct 2017 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted

2017 National Guideline Clearinghouse (partial archive)

142. Management of Type 2 Diabetes Mellitus

= generally should not be performed. Level of evidence supporting a diagnostic method or an intervention: A=randomized controlled trials; B=controlled trials, no randomization; C=observational trials; D=opinion of expert panel. 2 UMHS Management of Type 2 Diabetes Mellitus June, 2017 Table 1. Diagnosis of Diabetes: Diagnostic Tests and Glucose Values Diagnostic Test Normal Pre-diabetes Diabetes Hemoglobin A1c (A1c) a 30 mg/gm, check UA to rule out asymptomatic UTI. • Repeat spot urine ratio twice within 6 (...) for patients with type 2 diabetes. However, their use is rarely successful in patients with type 1 diabetes. 21 UMHS Management of Type 2 Diabetes Mellitus June, 2017 Symlin. Symlin is not a type of insulin but an amylinomimetic agent approved as adjunct therapy in patients with type 1 and type 2 diabetes who use mealtime insulin but who are not achieving optimal control. Symlin is used at mealtimes to augment the effects of insulin on glycemic control. This can cause hypoglycemia which can occur within 3

2017 University of Michigan Health System

143. Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians

cotransporter-2. Appendix Table 1. Summary of Clinical Outcomes for Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus Appendix Table 1. Summary of Clinical Outcomes for Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus Appendix Table 2. Summary of Intermediate Outcomes for Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus Appendix Table 2. Summary of Intermediate Outcomes for Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus Appendix Table 3. Summary of Harms for Oral (...) Pharmacologic Treatment of Type 2 Diabetes Mellitus Appendix Table 3. Summary of Harms for Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus Recommendations Recommendation 1: ACP recommends that clinicians prescribe metformin to patients with type 2 diabetes when pharmacologic therapy is needed to improve glycemic control. (Grade: strong recommendation; moderate-quality evidence) Metformin is effective in reducing glycemic levels, is associated with weight loss and fewer hypoglycemic episodes

Full Text available with Trip Pro

2017 American College of Physicians

144. Gliclazide for the treatment of type 2 diabetes mellitus

Gliclazide for the treatment of type 2 diabetes mellitus '); } else { document.write(' '); } ACE | Gliclazide for the treatment of type 2 diabetes mellitus Search > > Gliclazide for the treatment of type 2 diabetes mellitus - Gliclazide for the treatment of type 2 diabetes mellitus Published on 3 May 2017 Guidance Recommendations Following an evaluation of gliclazide for the treatment of type 2 diabetes mellitus, gliclazide 80mg immediate release tablet is recommended for listing on the MOH (...) Standard Drug List 1 (SDL1) by the MOH Drug Advisory Committee in view of its better safety profile compared to other sulfonylureas and low annual cost of subsidy. This recommendation means that subsidies will apply to gliclazide 80mg immediate release tablet for the indications registered in Singapore: Non-insulin-dependent diabetes, in association with an adapted diet, in cases where dietary measures alone provide inadequate control of blood glucose levels. Gliclazide 60mg modified release tablet

2017 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

145. Oral glucose-lowering agents in type 2 diabetes mellitus — an update

Oral glucose-lowering agents in type 2 diabetes mellitus — an update '); } else { document.write(' '); } ACE | Oral glucose-lowering agents in type 2 diabetes mellitus — an update Search > > Oral glucose-lowering agents in type 2 diabetes mellitus — an update - Oral glucose-lowering agents in type 2 diabetes mellitus — an update Published on 3 July 2017 This Appropriate Care Guide (ACG) highlights the importance of selecting agents based on drug and patient profiles to individualise care (...) ; and incorporates latest updates on oral glucose-lowering agents such as SGLT-2 inhibitors and DPP-4 inhibitors, their clinical and cost-effectiveness, safety and appropriate use in patients. Download the PDF below to access the full ACG. Key Messages 1. Establish patient-centred glycaemic targets. 2. Individualise treatment plans based on drug and patient profiles. 3. Select metformin as the initial glucose-lowering agent as it has long-term efficacy and safety data. 4. Use second generation sulfonylureas when

2017 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

146. Initiating basal insulin in type 2 diabetes mellitus

Initiating basal insulin in type 2 diabetes mellitus '); } else { document.write(' '); } ACE | Initiating basal insulin in type 2 diabetes mellitus Search > > Initiating basal insulin in type 2 diabetes mellitus - Initiating basal insulin in type 2 diabetes mellitus Published on 20 November 2017 This Appropriate Care Guide (ACG) continues from the ACG on oral glucose-lowering agents in type 2 diabetes mellitus (T2DM) and highlights the importance of not delaying insulin therapy. It provides (...) clinicians with a practical guide on initiating basal insulin in T2DM and how to prevent and manage hypoglycaemia. Download the PDF below to access the full ACG. Key Messages 1. Start insulin therapy if glycaemic goals are not met on oral glucose-lowering agents alone. 2. Initiate with basal insulin, such as intermediate- or long-acting insulin. 3. When initiating insulin, review concomitant oral glucose-lowering agents. Continue metformin +/- SGLT-2 inhibitors where appropriate. 4. Educate patients

2017 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

147. Hormone replacement therapy for women with type 1 diabetes mellitus. (PubMed)

Hormone replacement therapy for women with type 1 diabetes mellitus. There is conflicting information about the impact of the menopause on glycaemic control amongst women with type 1 diabetes. Some menopausal women with type 1 diabetes are treated with hormone replacement therapy (HRT) but the effects of this treatment have, to date, not been established.To assess the effects of HRT for women with type 1 diabetes mellitus.We searched The Cochrane Library, MEDLINE, EMBASE, CINAHL and PsycINFO (...) from their inception to June 2012. The last search was run for all databases on 18 June 2012.We selected randomised controlled trials or controlled clinical trials that involved peri- or postmenopausal women with type 1 diabetes undergoing HRT as an intervention.Two researchers independently applied the inclusion criteria to the identified studies and assessed risk of bias. Disagreements were resolved by discussion or by intervention by a third party. Descriptive analysis was conducted

Full Text available with Trip Pro

2013 Cochrane

148. Islet transplantation in patients with Type 1 Diabetes Mellitus

Islet transplantation in patients with Type 1 Diabetes Mellitus Islet transplantation in patients with Type 1 Diabetes Mellitus Islet transplantation in patients with Type 1 Diabetes Mellitus Xie X, Rich B, Dendukuri N Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Xie X, Rich B, Dendukuri N. Islet transplantation in patients with Type 1 Diabetes Mellitus (...) . Montreal: Technology Assessment Unit of the McGill University Health Centre (MUHC). Report no. 66. 2014 Authors' conclusions There is as yet insufficient evidence that IT is equal or superior to PT to justify its routine use when PT is the contemplated procedure. However, given its potential benefit, there is sufficient evidence of effectiveness and safety to justify its use in a limited number of patients. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Diabetes Mellitus

2014 Health Technology Assessment (HTA) Database.

149. Effects of different types of acute and chronic (training) exercise on glycaemic control in type 1 diabetes mellitus: a meta-analysis

Effects of different types of acute and chronic (training) exercise on glycaemic control in type 1 diabetes mellitus: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

150. Metformin?s role in type 1 diabetes: the removal trial

Tanner, MD, associate editor, clinical correlations Image courtesy of Wikimedia Commons References Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet . 1998;352(9131):854-865. Kaul K, Apostolopoulou M, Roden M. Insulin resistance in type 1 diabetes mellitus. Metabolism . 2015;64(12):1629-1639. Libman IM, Pietropaolo M, Arslanian SA, Laporte RE, Becker DJ. Changing (...) J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572. Anderson JJA, Couper JJ, Giles LC, et al. Effect of metformin on vascular function in children with type 1 diabetes: a 12-month randomized controlled trial. J Clin Endocrinol Metab . 2017;102(12):4448-4456. Ziaee A, Esmailzadehha N, Honardoost M. Comparison of adjunctive therapy with metformin and acarbose in patients with Type-1 diabetes mellitus. Pak J Med Sci

2019 Clinical Correlations

151. Type 1 diabetes

2 diabetes . This CKS topic does not cover the prescribing of insulin or the management of women with type 2 diabetes who are pregnant, planning 2016 2. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)- 1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus . BACKGROUND: The projected rise in the incidence of type 2 diabetes mellitus (T2DM) could develop (...) % up to 3% after surgery, an effect rarely equaled by medical treatment alone. In the SOS study, the remission rate for type 2 diabetes mellitus was 72% at 2 years and 36% at 10 2015 4. Newer Drugs for Type 2 Diabetes : An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes ? Newer Drugs for Type 2 Diabetes : An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes ? | CADTH.ca Français Français CADTH Document Viewer Newer Drugs for Type 2 Diabetes : An Emerging Adjunctive Therapy

2018 Trip Latest and Greatest

152. Is health related quality of life influenced by diabetic neuropathic pain among type II diabetes mellitus patients in Ethiopia? (PubMed)

diabetic peripheral neuropathy at two referral hospitals in Addis Ababa, Ethiopia, 2017.An institution based cross sectional study with internal comparison was conducted among a sample of 220 type II diabetes mellitus patients in a 1:1 matched ratio of those with and without diabetes associated peripheral neuropathic pain. All were having regular follow up at two hospitals in Addis Ababa, Ethiopia. The Short Form (SF-36) health-related quality of life instrument was used to collect data on quality (...) Is health related quality of life influenced by diabetic neuropathic pain among type II diabetes mellitus patients in Ethiopia? Polyneuropathy is one of the commonest complications of long-standing diabetes. Progressive sensory loss can predispose patients to foot ulcer and the neuropathy oftentimes causes pain. The pain can significantly affect the quality of life of patients.To describes the health-related quality of life of patients with type II diabetes mellitus suffering from painful

2019 PLoS ONE

153. High Sclerostin and Dickkopf-1 (DKK-1) Serum Levels in Children and Adolescents With Type 1 Diabetes Mellitus. (PubMed)

High Sclerostin and Dickkopf-1 (DKK-1) Serum Levels in Children and Adolescents With Type 1 Diabetes Mellitus. Childhood type 1 diabetes mellitus (T1DM) is associated with decreased bone mass. Sclerostin and dickkopf-1 (DKK-1) are Wnt inhibitors that regulate bone formation.To evaluate sclerostin and DKK-1 levels in T1DM children and to analyze the influence of glycemic control on bone health.Cross-sectional study conducted at a clinical research center.One hundred and six T1DM subjects (12.2 (...) ± 4 years), 66 on multiple daily injections (MDIs) and 40 on continuous subcutaneous infusion of insulin (CSII), and 80 controls.The average bone transmission time (BTT) and amplitude-dependent speed of sound (AD-SoS) z scores were lower in patients with diabetes than in controls. Significantly increased DKK-1 (3593 ± 1172 vs 2652 ± 689 pg/mL; P < 0.006) and sclerostin (29.45 ± 12.32 vs 22.53 ± 8.29; P < 0.001) levels were found in patients with diabetes with respect to controls, particularly

Full Text available with Trip Pro

2017 Journal of Clinical Endocrinology and Metabolism

154. Discovery Of Phosphorylated Peripherin As A Major Humoral Autoantigen In Type 1 Diabetes Mellitus (PubMed)

Discovery Of Phosphorylated Peripherin As A Major Humoral Autoantigen In Type 1 Diabetes Mellitus A major goal in understanding autoimmune diseases is to define the antigens that elicit a self-destructive immune response, but this is a difficult endeavor. In an effort to discover autoantigens associated with type 1 diabetes (T1D), we used epitope surrogate technology that screens combinatorial libraries of synthetic molecules for compounds that could recognize disease-linked autoantibodies

Full Text available with Trip Pro

2016 Cell chemical biology

155. The comparison of CHCA solvent compositions for improving LC-MALDI performance and its application to study the impact of aflatoxin B1 on the liver proteome of diabetes mellitus type 1 mice. (PubMed)

The comparison of CHCA solvent compositions for improving LC-MALDI performance and its application to study the impact of aflatoxin B1 on the liver proteome of diabetes mellitus type 1 mice. In nanoflow liquid chromatography-matrix-assisted laser desorption/ionization tandem time-of-flight (nanoLC-MALDI-TOF/TOF) approaches, it is critical to directly apply small amounts of the sample elutes on the sample target using a nanoLC system due to its low flow rate of 200 ~ 300 nl/min (...) of isopropanol (IPA): acetonitrile (ACN):acetone:0.1% Trifluoroacetic acid (TFA) (2:7:7:2) provided strong and homogeneous signals with higher peptide ion yields than the other solvent compositions. Then, nanoLC-MALDI-TOF/TOF was applied to study the impact of aflatoxin B1 on the liver proteome from diabetes mellitus type 1 mice. Aflatoxin B1 (AFB1), produced by Aspergillus flavus and Aspergillus parasiticus is a carcinogen and a known causative agent of liver cancer. To evaluate the effects of long-term

Full Text available with Trip Pro

2017 PLoS ONE

156. Prognosis of type 1 autoimmune pancreatitis after corticosteroid therapy-induced remission in terms of relapse and diabetes mellitus. (PubMed)

Prognosis of type 1 autoimmune pancreatitis after corticosteroid therapy-induced remission in terms of relapse and diabetes mellitus. Relapse and diabetes mellitus (DM) are major problems for the prognosis of autoimmune pancreatitis (AIP). We examined the prognosis of type 1 AIP after corticosteroid therapy (CST)-induced remission in terms of relapse and DM.The study enrolled 82 patients diagnosed with type 1 AIP who achieved remission with CST. We retrospectively evaluated the relapse rate

Full Text available with Trip Pro

2017 PLoS ONE

157. Plasma 1-deoxysphingolipids are early predictors of incident type 2 diabetes mellitus. (PubMed)

Plasma 1-deoxysphingolipids are early predictors of incident type 2 diabetes mellitus. 1-Deoxysphingolipids (1-deoxySLs) are atypical sphingolipids, which are formed in a side reaction during sphingolipid de-novo synthesis. Recently, we demonstrated that 1-deoxySLs are biomarkers for the prediction of T2DM in obese, non-diabetic patients. Here we investigated the relevance of 1-deoxySLs as long-term predictive biomarkers for the incidence of T2DM in an asymptomatic population. Here, we analyzed (...) the plasma sphingoid base profile in a nested group of non-diabetic individuals (N = 605) selected from a population-based study including 5 year follow-up data (CoLaus study). 1-DeoxySLs at baseline were significantly elevated in individuals who developed T2DM during the follow-up (p<0.001), together with increased glucose (p<5.11E-14), triglycerides (p<0.001) and HOMA-IR indices (p<0.001). 1-Deoxy-sphinganine (1-deoxySA) and 1-deoxy-sphingosine (1-deoxySO) were predictive for T2DM, even after adjusting

Full Text available with Trip Pro

2017 PLoS ONE

158. Circulating C1q complement/TNF-related protein (CTRP) 1, CTRP9, CTRP12 and CTRP13 concentrations in Type 2 diabetes mellitus: In vivo regulation by glucose. (PubMed)

Circulating C1q complement/TNF-related protein (CTRP) 1, CTRP9, CTRP12 and CTRP13 concentrations in Type 2 diabetes mellitus: In vivo regulation by glucose. The C1q complement/TNF-related protein (CTRP) superfamily, which includes the adipokine adiponectin, has been shown in animal models to have positive metabolic and cardiovascular effects. We sought to investigate circulating CTRP1, CTRP9, CTRP12 and CTRP13 concentrations in persons with type 2 diabetes mellitus (T2DM), with age and BMI

Full Text available with Trip Pro

2017 PLoS ONE

159. Diabetes (type 1 and type 2) in children and young people: diagnosis and management

with type 1 diabetes multiple daily injection basal–bolus insulin regimens from diagnosis. If a multiple daily injection regimen is not appropriate for a child or young person with type 1 diabetes, consider continuous subcutaneous insulin infusion (CSII or insulin pump) therapy as recommended in continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (NICE technology appraisal guidance 151). [new 2015] [new 2015] Dietary management for children and young people with type 1 (...) ://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 12 of 85diagnosis and classification of diabetes mellitus. [2004, amended 2015] [2004, amended 2015] 1.1.4 When diagnosing diabetes in a child or young person, assume type 1 diabetes unless there are strong indications of type 2 diabetes, monogenic or mitochondrial diabetes (see recommendations 1.1.5 and 1.1.6). [new 2015] [new 2015] 1.1.5 Think about the possibility of type 2 diabetes in children and young people with suspected diabetes who: have

2015 National Institute for Health and Clinical Excellence - Clinical Guidelines

160. Characterization of Adults With Type 1 Diabetes Not Attending Self-Management Education Courses: The Barriers to Uptake of Type 1 Diabetes Education (BUD1E) Study. (PubMed)

Characterization of Adults With Type 1 Diabetes Not Attending Self-Management Education Courses: The Barriers to Uptake of Type 1 Diabetes Education (BUD1E) Study. People with type 1 diabetes mellitus (T1DM) are offered attendance at diabetes self-management education courses to provide them with skills for self-management of flexible insulin dose adjustment. Attendance is poor, even when courses are evidence-based and nationally available. To understand barriers to attendance, we sought common (...) for barriers to attending diabetes self-management courses suggest strategies to improve attendance and extend the benefit of such courses more widely.

2019 Qualitative Health Research

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>